跳至主要内容
临床试验/2026-525256-29-00
2026-525256-29-00
已完成
1 期

Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.

ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.2 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2026年3月9日最近更新:

概览

阶段
1 期
状态
已完成
发起方
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
入组人数
36
试验地点
2

概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Clinical R&D

Scientific

ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.

研究点 (2)

Loading locations...

相似试验

尚未招募
1 期
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
2025-521732-11-00Laboratorios Cinfa S.A.32
已完成
1 期
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product Perampanel 12 mg film-coated tablets versus reference product Fycompa 12 mg film-coated tablets (Eisai GmbH) in healthy adult male and female subjects under fasting conditions.
2023-503345-59-00Laboratorios Cinfa S.A.36
尚未招募
1 期
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.
2025-524035-39-00Laboratorios Cinfa S.A.32
已完成
1 期
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product Perampanel 2 mg film-coated tablets versus reference product Fycompa 2 mg film-coated tablets (Eisai GmbH) in healthy adult male and female subjects under fasting conditions.
2023-504132-18-00Laboratorios Cinfa S.A.36
招募中
4 期
ACLR with suspensory and interference fixation
CTRI/2025/01/079716Dr. Rudra Prasad M S80